Supplementary Figure
Graphical depiction of the GSEA-SNP method. SNPs from pathway 1 (Set 1) show a higher degree of enrichment among SNPs with low P values within the list L than SNPs from pathway 2 (Set 2). Pathway 1 is more likely to be involved in the phenotype under investigation than pathway 2.
GSEA-SNP test results for a case-control data set
The GSEA-SNP method was applied to a SNP data set derived from a nested case-control study published elsewhere (Wojnowski, et al., 2005) . This study includes 52 cases and 52 matched controls from a cohort of patients with non-Hodgkin lymphoma. Cases developed cardiotoxicity following chemotherapy with anthracyclines, whereas controls did not. Controls and cases were matched according to age, sex, and treatment. Each of the 104 DNA samples was hybridized to a GeneChip Human Mapping 10K Xba 131 Array (Affymetrix, Santa Clara, CA), which contains 11555 SNPs. The assignment of these SNPs to genes was taken from the Affymetrix annotation file (www.affymetrix.com). After excluding the monomorph SNPs, SNPs with unknown gene annotation, SNPs not in Hardy-Weinberg equilibrium (in controls) and SNPs with a call-rate below 80%, 9446 SNPs remained for the GSEA-SNP analysis.
The SNPs-in-pathways analysis was conducted using the C2 curated gene set for pathway annotation (http://www.broad.mit.edu/gsea/msigdb/collections.jsp#C2). This catalogue contained 1892 gene sets, which we converted into 1892 SNP sets. SNP sets with less than 15 SNPs or more than 500 SNPs were excluded, leaving 1038 sets for the analysis. Of those, 18 were significant at the nominal significance level of 0.01, including several directly or indirectly linked to anthracycline-induced cardiotoxicity 1 : CDMACPATHWAY is associated with cell proliferation through activation of MAP kinase pathway. Genes constituting the pathway (e.g. MAPK, TNF, PRKCA) have been implicated in anthracycline-induced cardiotoxicity (Kang, et al., 2000; Zhu, et al., 1999) . OXSTRESS_BREASTCA_UP includes genes linked to electron transport and oxidoreductase activity, and thereby to oxidative stress underlying anthracycline-induced cardiotoxicity (Xiong, et al., 2006) . NI2_MOUSE_DN contains a number of genes involved in cell adhesion which also contribute to the development of this phenotype (Abou El Hassan, et al., 2003; Deng, et al., 2007) . Several genes from the LINDSTEDT_DEND_UP set are involved in apoptosis, cell death, cytokine and interleukin response which are also implicated in the cardiac response to anthracyclines (Kalyanaraman, et al., 2002) . Due to the small sample size, these intriguing insights into the genetic causes of doxorubicin-induced cardiotoxicity remain to be verified in further, larger clinical cohorts.
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